Introduction
Lyme borreliosis is a spirochaetal tick-borne disease caused by some genospecies of the Borrelia burgdorferi sensu lato complex. [1] [2] [3] [4] With 85 000 cases estimated annually in Europe and 300 000 cases estimated annually in the USA, it is the most common tick-borne disease in the northern hemi sphere. 5, 6 Nearly all human infections are caused by three B burgdorferi sensu lato genospecies: Borrelia garinii, Borrelia afzelii, and B burgdorferi sensu stricto. 1 All three species cause Lyme borreliosis in Europe, whereas only B burgdorferi sensu stricto causes Lyme borreliosis in the USA. 7 The clinical features of Lyme borreliosis are broad and seem to be associated with distinct tissue tropisms of specific B burgdorferi sensu lato genospecies. 8 Early localised infection typically results in erythema migrans rash, after which spirochaetes can disseminate to the nervous system, joints, and other organs. B burgdorferi sensu stricto is often associated with arthritis, B garinii with neurological effects, and B afzelii with acrodermatitis chronicum atrophicans. 8 Lyme borreliosis is characterised by a low level of spirochaetaemia. 9 Spirochaetes are detectable by PCR in the peripheral blood of less than 50% of patients with erythema migrans, with average estimation of about 2330 genome copies per mL, 9, 10 whereas the mean number of spirochaetes detected by culture of peripheral blood is only 0·1 spirochaetes per mL. 9 As expected, microscopic detection of B burgdorferi sensu lato spirochaetes has never been reported in peripheral blood, by marked contrast with relapsing fever borreliae, which have loads ranging from 10 5 spirochaetes per mL to more than 10 6 spirochaetes per mL, and are readily seen in peripheral blood. 11 We describe a new B burgdorferi sensu lato genospecies causing Lyme borreliosis with substantially elevated spirochaetaemia in acutely ill patients.
Methods

Patients
Mayo Medical Laboratories provides diagnostic PCR testing for Lyme borreliosis. 12 From Nov 1, 2003 , to Sept 30, 2014 , physicians throughout the USA submitted 100 545 specimens (synovial fluid, cerebrospinal fluid, EDTA [edetic acid]-anticoagulated whole blood, or fresh tissue) to our laboratory for routine clinical PCR testing. We interviewed patients with specimens yielding a PCR result that differed from that expected for B burgdorferi sensu stricto, B garinii, or B afzelii, to obtain clinical and epidemiological information. We reviewed medical records and requested additional samples. Patient followup and DNA sequencing of clinical specimens was approved by the Mayo Clinic institutional review board. Patients were interviewed by state public health officials as part of routine surveillance for a reportable condition.
Real-time PCR and DNA sequencing
We extracted DNA from diagnostic specimens using the MagNA Pure Instrument (Roche) and tested for B burgdorferi sensu stricto, B afzelii, and B garinii with a diagnostic real-time PCR assay that uses hybridisation probes and targets the chromosomal oppA1 gene. 12, 13 This assay is specific for B burgdorferi sensu lato and does not detect relapsing fever borreliae. We subjected PCR products to melting temperature analysis to differentiate B burgdorferi sensu lato genospecies (appendix). We established the number of oppA1 copies with standard curves that were prepared with genomic DNA from B burgdorferi sensu stricto B31 and the MN14-1420 isolate; oppA1 is present on the chromosome in a single copy in both genospecies. We used the Wilcoxon rank-sum test (two-sided) for oppA1 PCR crossing point comparison.
We amplified and sequenced portions of the 16S rDNA, ospC, flaB, rrf-rrl, oppA1, uvrA, rplB, recG, pyrG, pepX, clpX, nifS, and clpA genes using previously described primers. 12, [14] [15] [16] [17] We analysed, assembled, and trimmed sequences in Lasergene v9·0 (DNASTAR). Using BLAST, 16S rDNA, ospC, flaB, and rrf-rrl sequences were compared with B burgdorferi sensu lato and relapsing fever borreliae sequences in GenBank. For construction of phylogenetic trees, we obtained homologous B burgdorferi sensu lato and relapsing fever borreliae sequences from GenBank and PubMLST (appendix). We used MEGA 5 (ClustalW) to align sequences and trees constructed by maximum likelihood analysis using the generalised time-reversible nucleotide substitution model with gamma distribution (four categories) followed by bootstrap analysis (1000 replicates). 18 Housekeeping genes were concatenated in frame in the order uvrA, rplB, recG, pyrG, pepX, clpX, and clpA, with or without nifS and exported into MEGA 5 to calculate pairwise genetic distances using the Kimura-2 model.
Microscopy and culture
Two clinical blood specimens with an atypical oppA1 PCR melting temperature were available for microscopy and culture after storage at 4°C for either 5 days (one sample) or 39 days (one sample) (appendix). Other specimens were unavailable or previously frozen and not amenable to microscopy and culture. We examined wet mounts from patient samples and cultures with dark-field microscopy at 400 times magnification (appendix).
Serological testing
We tested serum samples and plasma samples for antibodies reacting to B burgdorferi sensu stricto using FDA-cleared commercially available kits, following the recommended twotiered algorithm (appendix). 19 
Tick collection and processing
We collected Ixodes scapularis ticks at approximate sites of possible patient exposure in Barron County, WI, USA, during 2013 and 2014 (appendix), and processed the ticks for PCR using a modification of a published protocol. 20 We also tested archived DNA from I scapularis collected in Eau Claire County, WI, USA, during 2009-10.
Role of the funding source
The funders of the study, Mayo Clinic and the US Centers for Disease Control and Prevention, had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
From Jan 1, 2012, to Sept 30, 2014 , 9197 clinical specimens from residents of Minnesota, Wisconsin, and North Dakota were submitted to Mayo Clinic, Rochester, MN, USA, for routine diagnostic B burgdorferi sensu lato oppA1 PCR testing. 3127 (34%) of 9197 specimens tested were blood samples, 1196 (13%) were synovial fluid, 4782 (52%) were cerebrospinal fluid, and 92 (1%) were tissue. 102 specimens were positive for B burgdorferi, including 13 blood, 81 synovial fluid, three cerebrospinal fluid, and five tissue samples. Six specimens (five blood, one synovial fluid) had positive oppA1 PCR results with an atypical melting temperature (60·38-61·24°C), falling between the expected melting temperature for B burgdorferi sensu stricto (61·7-66·7°C) and B afzelii or B garinii (51·7-56·7°C) (table 1, figure 1A , figure 2, appendix). 12 No atypical melting temperatures were identified among 24 786 clinical specimens tested from 44 other states during the same time period (FisherExact, p=0·00039), or among more than 66 562 clinical specimens from all states tested by the same method during 2003-11 (0 of 66 562 vs six of 33 983, p=0·00149). The five positive blood specimens with atypical melting temperatures were collected 1-4 days after onset of illness; the synovial fluid specimen was obtained 34 days after onset of illness (table 1). The median oppA1 PCR crossing point was significantly lower (median 29·82, IQR 28·89-30·75) for the five blood specimens with atypical oppA1 melting temperature compared with the 13 blood specimens that tested positive for B burgdorferi sensu stricto (median 34·51, IQR 33·73-35·55; p=0·0016; figure 3 ).
Sequence analysis of the atypical oppA1 PCR products that were directly amplified from three patient specimens identified a Borrelia species with 89-95% similarity to B burgdorferi sensu lato genospecies ( 
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Author Manuscript diluted blood) of the B burgdorferi sensu lato genospecies were microscopically recorded in blood from patient 6, obtained 1 day after illness onset and analysed 6 days later (figure 1B). The number of spirochaetes was estimated at around 8·5 × 10 4 /mL (appendix). No spirochaetes were seen in the haemolysed blood specimen from patient 5. Cultures of the B burgdorferi sensu lato genospecies (MN14-1420 and MN14-1539) were established from both available blood specimens (patients 5 and 6) after incubation for about 16 days. Spirochaetes were seen in primary and blind passaged cultures; sustained growth was achieved after cryopreservation and additional passage.
Based on the high quantity of spirochaetes that were detected microscopically, we estimated the number of oppA1 copies per mL of blood for all 18 specimens that tested positive for oppA1 PCR identified in Minnesota, Wisconsin, and North Dakota during 2012-14 by comparison of oppA1 crossing point values to standard curves prepared with B burgdorferi sensu stricto B31 or MN14-1420 (appendix). For the five atypical oppA1 positives, the median oppA1 copy number was 180 times higher (median 8·1 × 10 5 , IQR 4·6 × 10 5 -3·6 × 10 6 ) when compared with the 13 B burgdorferi sensu stricto positives (median 4·5 × 10 3 , IQR 2·3 × 10 3 -7·5 × 10 3 ; figure 3 ).
Sequence analysis of 16S rRNA (1327 nucleotides), ospC (561 base pairs), flaB (435 base pairs), and rrf-rrl (253 base pairs) amplified from the two blood isolates substantiated that the Borrelia species was not identical to any other Borrelia species in GenBank (appendix). The closest sequence identity was to B burgdorferi sensu lato genospecies at 99% for 16S RNA, 85% for ospC, 97% for flaB, and 95% for rrf-rrl. Multilocus sequence analysis of seven genes, uvrA, rplB, recG, pyrG, pepX, clpX, and clpA genes (3774 nucleotides), showed that the spirochaetes isolated from patients 5 and 6 fell within the B burgdorferi sensu lato genospecies complex and were the same B burgdorferi sensu lato genospecies amplified from the blood of patients 1, 2, and 3. The blood isolates were further compared with 18 B burgdorferi sensu lato genospecies and three relapsing fever borreliae using an eight-gene multilocus sequence analysis (uvrA, rplB, recG, pyrG, pepX, clpX, clpA, and nifS; 4335 nucleotides) previously described for defining B burgdorferi sensu lato genospecies 21 ( figure 4B ). The highest pairwise similarity was to B burgdorferi sensu stricto (94·9-95·2% similarity, genetic distance 0·051-0·048), well above the threshold defined for separating genospecies (98·3% similarity, genetic distance 0·017), 21 substantiating that the organism detected in the six patients is a novel B burgdorferi sensu lato genospecies, and not a relapsing fever borrelia (eg, B miyamotoi). For comparison, the genetic distance recorded between the novel B burgdorferi sensu lato genospecies and B burgdorferi sensu stricto B31/ Z41293 is greater than that seen between other formally recognised B burgdorferi sensu lato genospecies, including B bissetti and B kurtenbachii (0·035) and B garinii and B bavariensis (0·018). 14, 21 All patients were residents of the upper midwest (Minnesota, North Dakota, or Wisconsin) (figure 5). Median patient age was 36 years (range 10-67 years); four patients were male (table 1) . Five presented with acute febrile illnesses, including four with rash. The sixth patient was afebrile but had a 1-month history of unilateral knee pain and swelling. Two patients were admitted to hospital, but none had a known immunocompromising disorder. Testing showed lymphopenia (four of five tested), mild thrombocytopenia (two of five), and high hepatic transaminases (two of three). All patients reported onset of illness between May and July. Exposure to tick habitats in Minnesota or Wisconsin was reported by all patients and two recalled a tick bite less than 30 days before onset of illness. For one patient, the timing between tick bite and PCR sample acquisition was known to be 13 days.
Descriptions of illness-associated rash varied from diffuse macular rashes involving the face, trunk, and upper extremities (figure 1A, patients 1 and 5) to a single 2 cm diameter erythematous leg lesion at the tick bite location (patient 6; table 1). Patient 3 presented with a single annular erythematous leg lesion with central punctum consistent with erythema migrans, and developed fever, leg and arm pain, and diffuse macular rash on the trunk, upper and lower extremities, and face within 8 h of receiving doxycycline. Differential diagnosis included Jarisch-Herxheimer reaction, drug eruption, and erythema multiforme. Doxycycline was discontinued after one dose. The patient improved without additional treatment, but 3 weeks later developed three erythema migrans lesions on the back and leg, which resolved after treatment with cefuroxime.
All six patients were given antibiotics (table 1). All five patients with febrile illnesses recovered; one with preexisting anaemia reported continuing fatigue. The patient with arthritis improved but reported persistent joint pain 6 months after treatment. Serum or plasma was available for five patients and was tested for reactivity to B burgdorferi sensu stricto antigens using the recommended two-tiered algorithm 19 (table 2) . Patients 1, 3, and 4 were seropositive to B burgdorferi sensu stricto using this algorithm, including the 30 day cutoff for use of IgM immunoblot. Patient 5 had a positive EIA and IgM immunoblot in a sample obtained 32 days after onset of illness. All four seropositive patients had one or more samples positive using the first-tier C6 EIA; patients 3, 4, and 5 were positive using whole cell EIA. Two seropositive patients (3 and 5) had serial samples and sero converted from a negative to positive IgM immunoblot. The only specimen from patient 6 was obtained 1 day after illness onset and was seronegative.
Among archived and prospectively collected ticks I scapularis, 19 (2·9%, range 0-5·2%) of 658 were oppA1 PCR positive for the novel B burgdorferi sensu lato genospecies and 195 (29·6%, range 9·8-33·3%) of 658 were positive for B burgdorferi sensu stricto; two were positive for both. Sequence analysis of oppA1 for two ticks (EC10N1 and CP12150) and seven-gene multilocus sequence analysis for one tick (EC10N1) substantiated that the B burgdorferi sensu lato genospecies detected in I scapularis was the same identified in patients (figure 4A, appendix).
Discussion
We have identified a new B burgdorferi sensu lato genospecies (candidatus Borrelia mayonii) among patients and I scapularis ticks from the upper midwestern USA. A causal role in the patients' illnesses was suggested by the detection of DNA from this genospecies in patient specimens during acute illness, detection of motile spirochaetes in one blood specimen, culture of the novel B burgdorferi sensu lato genospecies from two patient specimens, development of a patient antibody response after illness onset, and clinical improvement after antimicrobial therapy active against other B burgdorferi sensu lato genospecies. Failure to identify the organism in more than 90 000 clinical samples tested in previous years and from other states might suggest that this new species recently emerged in the upper midwestern USA.
Using an eight-gene multilocus sequence analysis and a published threshold for delineation of B burgdorferi sensu lato genospecies, we showed that the Borrelia species is a member of the B burgdorferi sensu lato group.
Spirochaetes were seen in the diluted blood of a patient who presented with a single erythema migrans lesion, estimated by microscopy at 10 5 genome copies per mL. The number of genomes in this specimen, based on the single-copy chromosomal gene oppA1, was estimated independently at 5 × 10 5 per mL. Importantly, the median oppA1 copy number measured for the samples positive for B burgdorferi sensu stricto (4·5 × 10 2 per mL) agrees with that (2·3 × 10 2 /mL) recorded previously using quantitative flaB PCR, thus supporting the use of the oppA1 gene for B burgdorferi sensu lato quantitation. 10 For all five blood specimens from patients infected with the novel B burgdorferi sensu lato genospecies, the number of genomes was estimated to be 10 5 -10 6 genome copies per mL. This number is similar to what has been reported for patients infected with relapsing fever borreliae and 50-8000 times higher than the blood specimens that tested positive for B burgdorferi sensu stricto during the same time period. The number of spirochaetes as estimated by both microscopy and PCR in blood from patients infected with the novel B burgdorferi sensu lato genospecies is greater than previously estimated for Borrelia miyamotoi (10 3 -10 4 spirochaetes per mL of blood), a relapsing fever borreliae reported to cause human illness in the USA, Europe, and Russia. [22] [23] [24] [25] Whether this high spirochaetaemia suggests a different tissue tropism for the new B burgdorferi sensu lato genospecies is an important question that needs to be further addressed; five of six novel B burgdorferi sensu lato genospecies PCR positives were blood specimens, whereas only 13 (13%) of the 102 B burgdorferi sensu stricto PCR positives detected during the same time period were blood, and 81 (79%) of 102 samples were synovial fluids.
Patients infected with the novel B burgdorferi sensu lato genospecies presented with differing clinical presentations when compared with patients infected with B burgdorferi sensu stricto. At least two patients presented with diffuse macular rash not typical of erythema migrans, including one rash that might have involved the palms and soles. Four patients presented with nausea or vomiting and two with fever over 39°C, symptoms not usually reported for Lyme borreliosis 7,26-28 but often reported among patients infected with relapsing fever borreliae. 29 Similarly, three patients had symptoms potentially consistent with neurological effects (confused speech, profound somnolence, visual difficulties) and two were admitted to hospital.
An important issue raised by identification of the novel B burgdorferi sensu lato genospecies
is whether existing Lyme borreliosis diagnostic tests can detect infection with this organism. The six patients described here were fortuitously detected during routine clinical testing, because the diagnostic oppA1 PCR used at Mayo Clinic detects and differentiates B burgdorferi sensu lato genospecies by melting temperature analysis. However, it is unknown if diagnostic PCR assays specific for B burgdorferi sensu stricto will detect the novel genospecies. Regarding serology, the B burgdorferi sensu stricto C6 EIA was positive in all four patients with specimens obtained 3 days or more after onset of illness and B burgdorferi sensu stricto IgM immunoblots of specimens obtained 6 to 32 days after onset were positive for three patients. The B burgdorferi sensu stricto IgG immunoblot, however, was positive only for the patient with more than 30 days of untreated illness. B burgdorferi sensu stricto serology was negative for three specimens drawn 1-3 days after onset of illness.
The patients' infections were probably acquired by the bite of I scapularis, which transmits B burgdorferi sensu stricto in the USA. Two patients recalled a tick bite before illness and I scapularis that tested positive for the new B burgdorferi sensu lato genospecies were collected at two Wisconsin locations, including one visited by two patients. Prevalence of the novel species in tested I scapularis ranged from 0·6-4·9%. Non-detection of the new B burgdorferi sensu lato genospecies in I scapularis collected in the midwestern USA during 2004-07 further suggests that it might have recently emerged in this region. 30, 31 The identification of a novel B burgdorferi sensu lato genospecies causing Lyme borreliosis with substantially elevated spirochaetaemia and clinical features distinct from other recognised B burgdorferi sensu lato genospecies has important implications for accurate diagnosis, treatment and disease reporting. In view of the differing clinical manifestations for patients infected with the novel B burgdorferi sensu lato genospecies, it is likely that Lyme borreliosis is not being considered-and therefore not diagnosed-in some patients with this infection. The clinical range of illness must be better defined in additional patients to ensure that physicians can recognise the infection and distinguish it from other tick-borne infections. Many tick-borne pathogens have global distribution, therefore studies are needed to establish the geographic distribution of human beings and ticks infected with the novel B burgdorferi sensu lato genopecies. Finally, clinicians should be aware of the potential role of oppA1 PCR for diagnosing infection with this novel pathogen.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. 
Research in context
Evidence before this study Lyme borreliosis is a multisystem tick-borne disease of wide public health significance. It is the most frequently reported vector-borne disease in the temperate northern hemisphere and is caused by spirochaetes in the Borrelia burgdorferi sensu lato genospecies complex.
There have been no previous descriptions of the pathogenic Borrelia species reported in this study in either ticks or human beings, or reports of Lyme borreliosis with high spirochaetaemia.
Added value of this study
The identification of a new B burgdorferi sensu lato genospecies causing Lyme borreliosis with substantially elevated spirochaetaemia and clinical features distinct from other B burgdorferi sensu lato genospecies has important implications for accurate diagnosis and treatment. In view of the differing clinical manifestations for patients infected with the novel B burgdorferi sensu lato genospecies, it is likely that Lyme borreliosis is not being considered in some patients with this infection. The medical and health-care community need to be aware of this new pathogen to recognise the infection and to treat patients appropriately.
Implications of all the available evidence
The discovery of a novel B burgdorferi sensu lato genospecies was attributable to the use of a diagnostic real-time PCR assay that detects and differentiates B burgdorferi sensu lato genospecies by melting temperature analysis. Those PCR assays designed specifically for detection of a single B burgdorferi sensu lato genospecies do not have the same ability to identify new or different genospecies. Since many tick-borne human pathogens have a global distribution (eg, B burgdorferi, Babesia microti, Anaplasma phagocytophilum, Ehrlichia muris, and Borrelia miyamotoi), the emergence of this pathogen highlights the need for widespread surveillance to look for emergence of this organism or related species in other parts of the world. oppA1 gene sequence was generated in this study. Table 2 Serological test results from patients infected with the novel B burgdorferi sensu lato genospecies 
